Dr. Brian Ogilvie is the VP of Scientific Consulting at BioIVT where he leads a team that advises clients on in vitro drug-drug interaction studies and program strategy. He received a Ph.D. in toxicology from the University of Kansas Medical Center. He has published various research articles and book chapters and has been an invited speaker at numerous drug development conferences.